Tags Posts tagged with "pharmaceuticals"

pharmaceuticals

Amazon continues to stay mum on its healthcare ambitions but if you put the pieces together, it’s clear there’s some sort of play in the works. This past year, rumors swirled around the clandestine 1492 lab, focused, among other things, on electronic...

This quarter has been abuzz with activity for the Canadian cannabis sector.  The provinces continue to roll out their distribution plans, and in November, Health Canada tabled its proposed regulatory framework.  In the private sector, Aurora Cannabis launched a hostile takeover...

As recently noted in a Wall Street Journal article, some private equity (PE) firms have begun partnering with pharmaceutical companies, though in a manner far from traditional. Instead of buying nascent fledgling biotech firms outright, these PE companies have begun providing...

In contrast to M&A levels in many other sectors, deal making activity in the pharmaceutical and biotechnology industries remained strong in 2016, but is this area likely to stay hot in 2017? In the latest edition of our quarterly report series, Firmex...
video

Canadian Health Minister Jane Philpott’s cheeky use of April 20 – 4/20 in pot smokers’ code – to set a one-year timeline for legalization of recreational marijuana spells an important day for the marijuana industry as a whole. Shortly after the...

Inversion deals, a controversial tax arrangement in which a business incorporates in another country to avoid paying U.S. corporate taxes, have come under fire in a new way recently.

Tempting overseas tax rates are encouraging many U.S. companies to pursue cross-border deals. A number of deal inversions have been explored or attempted in the last two years alone.

Monoclonal antibodies (mAbs) represent one of the most successful therapeutic drug classes, attracting billions of investment dollars for the biotechnology industry. Last week AstraZeneca’s global biologics research and development arm, MedImmune, became the latest mAb player. MedImmune acquired Spirogen, a privately held...

2012 was a healthy year for the U.S. pharmaceuticals industry, with 39 new drugs approved - the highest in 16 years. This trend was largely driven by a string of recent patent expirations, with generic drug makers able to offer cheaper alternatives...

Today we enjoyed an in-depth discussion of The Regulatory Cooperation Council (RCC) with Emily Larose, partner in the advocacy group at Cassels Brock. Her insights into how the RCC and the Border Action plan are impacting cross-border business in agriculture and food,...